Neurodegenerative Disease Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	250 Pages	Future Market Insights	June, 2022	FMARI18055949

Best Price Guarantee
Price	from $5,000
Length	250 Pages
Publisher	Future Market Insights
Published Date	June, 2022
SKU	FMARI18055949

Neurodegenerative Disease Market

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Neurodegeneration is a broader term which comprises of different disease namely Parkinson’s disease, Huntington disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. These are the most commonly occurring diseases under the condition “Neurodegeneration”. Neurodegeneration can be caused due to genetic factor but the proportion is minimal. Major cause of neurodegeneration could be deposition of toxic protein substance in the brain or loss of functionality/improper functioning of mitochondria present in brain. Patients generally show mixture of symptoms for one or more neurodegenerative disease. Currently there is no cure for this condition however specific drugs are present in the market to minimize the symptoms (for example: donepezil and memantine for Alzheimer’s disease, L-dopa for Parkinson’s, riluzole for ALS).

Neurodegenerative Disease Market: Drivers & Restraints

Neurodegenerative market is expected to dwell due to continuous advancement in medical technology both for the diagnosis and the treatment of neurological disorders have raised the demand of neurodegenerative drugs. Ageing population is increasing which in turn is leading to increase in the incidence of neurological disorders are some major factors driving the growth of neurodegenerative market. Growing awareness amongst the physicians is helping the market to dwell in developed countries. Developing countries especially Asia Pacific countries, where due to large population the market growth is expected to be significant in the upcoming years. Lack of complete curative treatment measures primarily because of the manifold nature of the disease could possibly hamper the market of neurodegenerative disease market at the global level.

Neurodegenerative Market: Segmentation

Neurodegenerative market is classified on the basis of Drug class, indications and geography.

Based on Drug class, the global Neurodegenerative disease market is segmented into the following:

NMDA
SSRIs
Dopamine Inhibitors
Based on Indications, the global Neurodegenerative disease market is segmented into the following:

Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease
Neurodegenerative Disease Market: Overview

Neurodegenerative disease market is expected to grow at a significant pace mainly due to increasing cases of neurological disorders. The market is expected to witness advancement in the upcoming years due to launch of new type of drugs. In the Alzheimer’s market, drugs like GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists are expected to influence the market growth however in the Parkinson’s disease market will be driven due to launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists. New players are expected to enter the market in the forecast years due to patent protection loss for major players.

Neurodegenerative Market: Region-wise Outlook

Depending on geographic regions, global neurodegenerative disease market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Global market for neurodegenerative disease is expected to grow by a CAGR of around 5%. Asia Pacific is expected to witness the highest growth due to large population base over the forecast years.

Neurodegenerative Market: Key Players

Some of the key market players in global Neurodegenerative market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline to name a few. Major players will face competition in the upcoming years due to patent protection loss.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Rest of Western Europe)
Eastern Europe (Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

1. Executive Summary: 1.1. Global Market Outlook; 1.2. Demand-side Trends; 1.3. Supply-side Trends; 1.4. Technology Roadmap Analysis; 1.5. Analysis and Recommendations
2. Market Overview: 2.1. Market Coverage / Taxonomy; 2.2. Market Definition / Scope / Limitations
3. Market Background: 3.1. Market Dynamics; 3.1.1. Drivers; 3.1.2. Restraints; 3.1.3. Opportunity; 3.1.4. Trends; 3.2. Scenario Forecast; 3.2.1. Demand in Optimistic Scenario; 3.2.2. Demand in Likely Scenario; 3.2.3. Demand in Conservative Scenario; 3.3. Opportunity Map Analysis; 3.4. Investment Feasibility Matrix; 3.5. PESTLE and Porter’s Analysis; 3.6. Regulatory Landscape; 3.6.1. By Key Regions; 3.6.2. By Key Countries; 3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032: 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021; 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032; 4.2.1. Y-o-Y Growth Trend Analysis; 4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication: 5.1. Introduction / Key Findings; 5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication, 2017-2021; 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication, 2022-2032; 5.3.1. Alzheimer’s Disease; 5.3.2. Motor Neuron Diseases; 5.3.3. Parkinson’s Disease; 5.3.4. Huntington’s Disease; 5.3.5. Multiple Sclerosis; 5.3.6. Others; 5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017-2021; 5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022-2032; Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class: 6.1. Introduction / Key Findings; 6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021; 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032; 6.3.1. Cholinesterase Inhibitors; 6.3.2. Dopamine Inhibitors; 6.3.3. MAO-B Inhibitors; 6.3.4. Catechol-O-methyltransferase Inhibitors; 6.3.5. Anticholinergics; 6.3.6. Antipsychotic Drugs; 6.3.7. Dopamine Antagonists; 6.3.8. Others; 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021; 6.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032; Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration: 7.1. Introduction / Key Findings; 7.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021; 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032; 7.3.1. Oral Drugs; 7.3.2. Parenteral Drugs; 7.3.3. Topical Drugs; 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021; 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032; Deep-dive segmentation will be available in the sample on request
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel: 8.1. Introduction / Key Findings; 8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021; 8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032; 8.3.1. Hospital Pharmacies; 8.3.2. Retail Pharmacies; 8.3.3. Online Pharmacies; 8.3.4. Drug Stores; 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021; 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032; Deep-dive segmentation will be available in the sample on request
9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region: 9.1. Introduction; 9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021; 9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032; 9.3.1. North America; 9.3.2. Latin America; 9.3.3. Europe; 9.3.4. East Asia; 9.3.5. South Asia & Pacific; 9.3.6. MEA; 9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 10.2.1. By Country; 10.2.1.1. U.K.; 10.2.1.2. Canada; 10.2.2. By Disease Indication; 10.2.3. By Drug Class; 10.2.4. By Route of Administration; 10.2.5. By Distribution Channel; 10.3. Market Attractiveness Analysis; 10.3.1. By Country; 10.3.2. By Disease Indication; 10.3.3. By Drug Class; 10.3.4. By Route of Administration; 10.3.5. By Distribution Channel; 10.4. Key Takeaways
11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 11.2.1. By Country; 11.2.1.1. Brazil; 11.2.1.2. Mexico; 11.2.1.3. Rest of Latin America; 11.2.2. By Disease Indication; 11.2.3. By Drug Class; 11.2.4. By Route of Administration; 11.2.5. By Distribution Channel; 11.3. Market Attractiveness Analysis; 11.3.1. By Country; 11.3.2. By Disease Indication; 11.3.3. By Drug Class; 11.3.4. By Route of Administration; 11.3.5. By Distribution Channel; 11.4. Key Takeaways
12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 12.2.1. By Country; 12.2.1.1. Germany; 12.2.1.2. U.K.; 12.2.1.3. France; 12.2.1.4. Spain; 12.2.1.5. Italy; 12.2.1.6. Rest of Europe; 12.2.2. By Disease Indication; 12.2.3. By Drug Class; 12.2.4. By Route of Administration; 12.2.5. By Distribution Channel; 12.3. Market Attractiveness Analysis; 12.3.1. By Country; 12.3.2. By Disease Indication; 12.3.3. By Drug Class; 12.3.4. By Route of Administration; 12.3.5. By Distribution Channel; 12.4. Key Takeaways
13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 13.2.1. By Country; 13.2.1.1. China; 13.2.1.2. Japan; 13.2.1.3. South Korea; 13.2.2. By Disease Indication; 13.2.3. By Drug Class; 13.2.4. By Route of Administration; 13.2.5. By Distribution Channel; 13.3. Market Attractiveness Analysis; 13.3.1. By Country; 13.3.2. By Disease Indication; 13.3.3. By Drug Class; 13.3.4. By Route of Administration; 13.3.5. By Distribution Channel; 13.4. Key Takeaways
14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 14.2.1. By Country; 14.2.1.1. India; 14.2.1.2. Thailand; 14.2.1.3. Indonesia; 14.2.1.4. Malaysia; 14.2.1.5. Singapore; 14.2.1.6. Australia; 14.2.1.7. New Zealand; 14.2.1.8. Rest of South Asia & Pacific; 14.2.2. By Disease Indication; 14.2.3. By Drug Class; 14.2.4. By Route of Administration; 14.2.5. By Distribution Channel; 14.3. Market Attractiveness Analysis; 14.3.1. By Country; 14.3.2. By Disease Indication; 14.3.3. By Drug Class; 14.3.4. By Route of Administration; 14.3.5. By Distribution Channel; 14.4. Key Takeaways
15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country: 15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021; 15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032; 15.2.1. By Country; 15.2.1.1. GCC Countries; 15.2.1.2. South Africa; 15.2.1.3. Israel; 15.2.1.4. Rest of MEA; 15.2.2. By Disease Indication; 15.2.3. By Drug Class; 15.2.4. By Route of Administration; 15.2.5. By Distribution Channel; 15.3. Market Attractiveness Analysis; 15.3.1. By Country; 15.3.2. By Disease Indication; 15.3.3. By Drug Class; 15.3.4. By Route of Administration; 15.3.5. By Distribution Channel; 15.4. Key Takeaways
16. Key Countries Market Analysis: 16.1. U.K.; 16.1.1. Pricing Analysis; 16.1.2. Market Share Analysis, 2021; 16.1.2.1. By Disease Indication; 16.1.2.2. By Drug Class; 16.1.2.3. By Route of Administration; 16.1.2.4. By Distribution Channel; 16.2. Canada; 16.2.1. Pricing Analysis; 16.2.2. Market Share Analysis, 2021; 16.2.2.1. By Disease Indication; 16.2.2.2. By Drug Class; 16.2.2.3. By Route of Administration; 16.2.2.4. By Distribution Channel; 16.3. Brazil; 16.3.1. Pricing Analysis; 16.3.2. Market Share Analysis, 2021; 16.3.2.1. By Disease Indication; 16.3.2.2. By Drug Class; 16.3.2.3. By Route of Administration; 16.3.2.4. By Distribution Channel; 16.4. Mexico; 16.4.1. Pricing Analysis; 16.4.2. Market Share Analysis, 2021; 16.4.2.1. By Disease Indication; 16.4.2.2. By Drug Class; 16.4.2.3. By Route of Administration; 16.4.2.4. By Distribution Channel; 16.5. Germany; 16.5.1. Pricing Analysis; 16.5.2. Market Share Analysis, 2021; 16.5.2.1. By Disease Indication; 16.5.2.2. By Drug Class; 16.5.2.3. By Route of Administration; 16.5.2.4. By Distribution Channel; 16.6. U.K.; 16.6.1. Pricing Analysis; 16.6.2. Market Share Analysis, 2021; 16.6.2.1. By Disease Indication; 16.6.2.2. By Drug Class; 16.6.2.3. By Route of Administration; 16.6.2.4. By Distribution Channel; 16.7. France; 16.7.1. Pricing Analysis; 16.7.2. Market Share Analysis, 2021; 16.7.2.1. By Disease Indication; 16.7.2.2. By Drug Class; 16.7.2.3. By Route of Administration; 16.7.2.4. By Distribution Channel; 16.8. Spain; 16.8.1. Pricing Analysis; 16.8.2. Market Share Analysis, 2021; 16.8.2.1. By Disease Indication; 16.8.2.2. By Drug Class; 16.8.2.3. By Route of Administration; 16.8.2.4. By Distribution Channel; 16.9. Italy; 16.9.1. Pricing Analysis; 16.9.2. Market Share Analysis, 2021; 16.9.2.1. By Disease Indication; 16.9.2.2. By Drug Class; 16.9.2.3. By Route of Administration; 16.9.2.4. By Distribution Channel; 16.10. China; 16.10.1. Pricing Analysis; 16.10.2. Market Share Analysis, 2021; 16.10.2.1. By Disease Indication; 16.10.2.2. By Drug Class; 16.10.2.3. By Route of Administration; 16.10.2.4. By Distribution Channel; 16.11. Japan; 16.11.1. Pricing Analysis; 16.11.2. Market Share Analysis, 2021; 16.11.2.1. By Disease Indication; 16.11.2.2. By Drug Class; 16.11.2.3. By Route of Administration; 16.11.2.4. By Distribution Channel; 16.12. South Korea; 16.12.1. Pricing Analysis; 16.12.2. Market Share Analysis, 2021; 16.12.2.1. By Disease Indication; 16.12.2.2. By Drug Class; 16.12.2.3. By Route of Administration; 16.12.2.4. By Distribution Channel; 16.13. India; 16.13.1. Pricing Analysis; 16.13.2. Market Share Analysis, 2021; 16.13.2.1. By Disease Indication; 16.13.2.2. By Drug Class; 16.13.2.3. By Route of Administration; 16.13.2.4. By Distribution Channel; 16.14. Thailand; 16.14.1. Pricing Analysis; 16.14.2. Market Share Analysis, 2021; 16.14.2.1. By Disease Indication; 16.14.2.2. By Drug Class; 16.14.2.3. By Route of Administration; 16.14.2.4. By Distribution Channel; 16.15. Indonesia; 16.15.1. Pricing Analysis; 16.15.2. Market Share Analysis, 2021; 16.15.2.1. By Disease Indication; 16.15.2.2. By Drug Class; 16.15.2.3. By Route of Administration; 16.15.2.4. By Distribution Channel; 16.16. Malaysia; 16.16.1. Pricing Analysis; 16.16.2. Market Share Analysis, 2021; 16.16.2.1. By Disease Indication; 16.16.2.2. By Drug Class; 16.16.2.3. By Route of Administration; 16.16.2.4. By Distribution Channel; 16.17. Singapore; 16.17.1. Pricing Analysis; 16.17.2. Market Share Analysis, 2021; 16.17.2.1. By Disease Indication; 16.17.2.2. By Drug Class; 16.17.2.3. By Route of Administration; 16.17.2.4. By Distribution Channel; 16.18. Australia; 16.18.1. Pricing Analysis; 16.18.2. Market Share Analysis, 2021; 16.18.2.1. By Disease Indication; 16.18.2.2. By Drug Class; 16.18.2.3. By Route of Administration; 16.18.2.4. By Distribution Channel; 16.19. New Zealand; 16.19.1. Pricing Analysis; 16.19.2. Market Share Analysis, 2021; 16.19.2.1. By Disease Indication; 16.19.2.2. By Drug Class; 16.19.2.3. By Route of Administration; 16.19.2.4. By Distribution Channel; 16.20. GCC Countries; 16.20.1. Pricing Analysis; 16.20.2. Market Share Analysis, 2021; 16.20.2.1. By Disease Indication; 16.20.2.2. By Drug Class; 16.20.2.3. By Route of Administration; 16.20.2.4. By Distribution Channel; 16.21. South Africa; 16.21.1. Pricing Analysis; 16.21.2. Market Share Analysis, 2021; 16.21.2.1. By Disease Indication; 16.21.2.2. By Drug Class; 16.21.2.3. By Route of Administration; 16.21.2.4. By Distribution Channel; 16.22. Israel; 16.22.1. Pricing Analysis; 16.22.2. Market Share Analysis, 2021; 16.22.2.1. By Disease Indication; 16.22.2.2. By Drug Class; 16.22.2.3. By Route of Administration; 16.22.2.4. By Distribution Channel
17. Market Structure Analysis: 17.1. Competition Dashboard; 17.2. Competition Benchmarking; 17.3. Market Share Analysis of Top Players; 17.3.1. By Regional; 17.3.2. By Disease Indication; 17.3.3. By Drug Class; 17.3.4. By Route of Administration; 17.3.5. By Distribution Channel
18. Competition Analysis: 18.1. Competition Deep Dive; 18.1.1. F. Hoffmann-La Roche Ltd; 18.1.1.1. Overview; 18.1.1.2. Product Portfolio; 18.1.1.3. Profitability by Market Segments; 18.1.1.4. Sales Footprint; 18.1.1.5. Strategy Overview; 18.1.1.5.1. Marketing Strategy; 18.1.2. Novartis AG; 18.1.2.1. Overview; 18.1.2.2. Product Portfolio; 18.1.2.3. Profitability by Market Segments; 18.1.2.4. Sales Footprint; 18.1.2.5. Strategy Overview; 18.1.2.5.1. Marketing Strategy; 18.1.3. Biogen; 18.1.3.1. Overview; 18.1.3.2. Product Portfolio; 18.1.3.3. Profitability by Market Segments; 18.1.3.4. Sales Footprint; 18.1.3.5. Strategy Overview; 18.1.3.5.1. Marketing Strategy; 18.1.4. Teva Pharmaceuticals Industries Ltd.; 18.1.4.1. Overview; 18.1.4.2. Product Portfolio; 18.1.4.3. Profitability by Market Segments; 18.1.4.4. Sales Footprint; 18.1.4.5. Strategy Overview; 18.1.4.5.1. Marketing Strategy; 18.1.5. Eisai Co., Ltd.; 18.1.5.1. Overview; 18.1.5.2. Product Portfolio; 18.1.5.3. Profitability by Market Segments; 18.1.5.4. Sales Footprint; 18.1.5.5. Strategy Overview; 18.1.5.5.1. Marketing Strategy; 18.1.6. Sanofi; 18.1.6.1. Overview; 18.1.6.2. Product Portfolio; 18.1.6.3. Profitability by Market Segments; 18.1.6.4. Sales Footprint; 18.1.6.5. Strategy Overview; 18.1.6.5.1. Marketing Strategy; 18.1.7. Merck KGaA; 18.1.7.1. Overview; 18.1.7.2. Product Portfolio; 18.1.7.3. Profitability by Market Segments; 18.1.7.4. Sales Footprint; 18.1.7.5. Strategy Overview; 18.1.7.5.1. Marketing Strategy; 18.1.8. UCB S.A; 18.1.8.1. Overview; 18.1.8.2. Product Portfolio; 18.1.8.3. Profitability by Market Segments; 18.1.8.4. Sales Footprint; 18.1.8.5. Strategy Overview; 18.1.8.5.1. Marketing Strategy; 18.1.9. Boehringer Ingelheim International GmbH; 18.1.9.1. Overview; 18.1.9.2. Product Portfolio; 18.1.9.3. Profitability by Market Segments; 18.1.9.4. Sales Footprint; 18.1.9.5. Strategy Overview; 18.1.9.5.1. Marketing Strategy; 18.1.10. GlaxoSmithKline plc; 18.1.10.1. Overview; 18.1.10.2. Product Portfolio; 18.1.10.3. Profitability by Market Segments; 18.1.10.4. Sales Footprint; 18.1.10.5. Strategy Overview; 18.1.10.5.1. Marketing Strategy; 18.1.11. Neuro-Hitech, Inc.; 18.1.11.1. Overview; 18.1.11.2. Product Portfolio; 18.1.11.3. Profitability by Market Segments; 18.1.11.4. Sales Footprint; 18.1.11.5. Strategy Overview; 18.1.11.5.1. Marketing Strategy; 18.1.12. BioVision Inc; 18.1.12.1. Overview; 18.1.12.2. Product Portfolio; 18.1.12.3. Profitability by Market Segments; 18.1.12.4. Sales Footprint; 18.1.12.5. Strategy Overview; 18.1.12.5.1. Marketing Strategy; 18.1.13. Aquinnah Pharmaceuticals; 18.1.13.1. Overview; 18.1.13.2. Product Portfolio; 18.1.13.3. Profitability by Market Segments; 18.1.13.4. Sales Footprint; 18.1.13.5. Strategy Overview; 18.1.13.5.1. Marketing Strategy; 18.1.14. ADDEX THERAPEUTICS; 18.1.14.1. Overview; 18.1.14.2. Product Portfolio; 18.1.14.3. Profitability by Market Segments; 18.1.14.4. Sales Footprint; 18.1.14.5. Strategy Overview; 18.1.14.5.1. Marketing Strategy; 18.1.15. Cellcentric; 18.1.15.1. Overview; 18.1.15.2. Product Portfolio; 18.1.15.3. Profitability by Market Segments; 18.1.15.4. Sales Footprint; 18.1.15.5. Strategy Overview; 18.1.15.5.1. Marketing Strategy; 18.1.16. Mission Therapeutics; 18.1.16.1. Overview; 18.1.16.2. Product Portfolio; 18.1.16.3. Profitability by Market Segments; 18.1.16.4. Sales Footprint; 18.1.16.5. Strategy Overview; 18.1.16.5.1. Marketing Strategy; 18.1.17. CogRx; 18.1.17.1. Overview; 18.1.17.2. Product Portfolio; 18.1.17.3. Profitability by Market Segments; 18.1.17.4. Sales Footprint; 18.1.17.5. Strategy Overview; 18.1.17.5.1. Marketing Strategy; 18.1.18. Denali Therapeutics Inc; 18.1.18.1. Overview; 18.1.18.2. Product Portfolio; 18.1.18.3. Profitability by Market Segments; 18.1.18.4. Sales Footprint; 18.1.18.5. Strategy Overview; 18.1.18.5.1. Marketing Strategy; 18.1.19. Psyadon Pharmaceuticals, Inc.; 18.1.19.1. Overview; 18.1.19.2. Product Portfolio; 18.1.19.3. Profitability by Market Segments; 18.1.19.4. Sales Footprint; 18.1.19.5. Strategy Overview; 18.1.19.5.1. Marketing Strategy; 18.1.20. Cipla Inc.; 18.1.20.1. Overview; 18.1.20.2. Product Portfolio; 18.1.20.3. Profitability by Market Segments; 18.1.20.4. Sales Footprint; 18.1.20.5. Strategy Overview; 18.1.20.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology